Federal Trade Commission v. Illumina Inc.

CourtDistrict Court, S.D. California
DecidedApril 20, 2021
Docket3:21-cv-00800
StatusUnknown

This text of Federal Trade Commission v. Illumina Inc. (Federal Trade Commission v. Illumina Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Federal Trade Commission v. Illumina Inc., (S.D. Cal. 2021).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA FEDERAL TRADE COMMISSION, : : Plaintiff, : Civil Action No.: 21-873 (RC) : v. : Re Document No.: 41 : ILLUMINA, INC., et al., : : Defendants. : MEMORANDUM OPINION GRANTING DEFENDANT’S MOTION TO TRANSFER VENUE I. INTRODUCTION Two biotechnology firms agreed that one would acquire the other. The federal government then filed suit to stop the merger, arguing that the deal would stifle innovation and harm consumers. But before any court can decide whether the merger can go forward, this Court must determine where the litigation should take place. Between this district and a district that would be easier for the most witnesses to get to, the latter is more appropriate. II. BACKGROUND Illumina, Inc. is a market leader in genetic sequencing products. Redacted Compl. ¶¶ 5– 6, ECF No. 14. Its sequencing platforms are a key component in multi-cancer early detection tests, which promise to revolutionize cancer treatment. Id. ¶¶ 2, 6. These tests will allow healthcare providers to screen for a wide variety of cancers and detect cancer early on in a tumor’s development. Id. ¶¶ 2–3. Several biotechnology firms are racing to develop the technology and bring it to market. Id. ¶ 4. In 2015, Illumina formed GRAIL, Inc. to compete in that race. Id. ¶ 7. Two years later, however, Illumina reduced its share in GRAIL to below 20%. Id. ¶ 8. It currently owns just 14.5% of GRAIL’s voting shares, with well-known investors like Jeff Bezos, Bill Gates, and Johnson & Johnson owning the rest. Id. GRAIL has now developed a multi-cancer early

detection test called “Galleri.” Id. ¶¶ 4, 9. It plans to seek approval to commercialize Galleri from the U.S. Food and Drug Administration (“FDA”). Id. ¶ 9. Last year, Illumina and GRAIL (collectively, “Defendants”) entered into a merger agreement whereby Illumina would acquire the remaining 85.5% of GRAIL’s shares it does not already own. Id. ¶ 26. Concerned that the merger would have serious anticompetitive effects on the U.S. multi- cancer early detection test market, see id. ¶¶ 1, 11–14, the Federal Trade Commission decided to conduct an administrative adjudication to determine if the deal would violate federal antitrust laws, id. ¶ 27. That adjudication is scheduled to begin in the District of Columbia on August 24, 2021. See id.; Pl.’s Mem. Opp’n Defs.’ Mot. Transfer Venue (“Pl.’s Opp’n”) at 11, ECF No. 55. To prevent Defendants from executing the merger while the adjudication is pending, the

Commission filed this action. See Pl.’s Mot. TRO, ECF No. 4. The parties have stipulated to a temporary restraining order that prevents the merger until the earliest of (1) September 20, 2021; (2) the end of the second business day after a court rules on the Commission’s motion for a preliminary injunction; or (3) the Commission’s dismissal of the action. TRO at 2, ECF No. 8. The dispute at issue now is which court should decide the Commission’s preliminary injunction motion. Defendants ask that the case be transferred to the Southern District of California. See Mem. P & A Supp. Defs.’ Mot. Transfer Venue (“Defs.’ Mot.”), ECF No. 41-1. Both companies are headquartered in California—Illumina in the Southern District, Schwillinksi Decl. ¶ 4, ECF No. 41-3, and GRAIL in the Northern District, Song Decl. ¶ 3, ECF No. 41-2. California was also the site of the merger negotiations. Schwillinksi Decl. ¶ 5; Song Decl. ¶ 6. And Defendants say that, if an in-person hearing on the motion is possible, more witnesses would have an easier time getting to the Southern District than this one. Defs.’ Mot. at 1–2. The Commission opposes transfer. See Pl.’s Opp’n. It stresses that its choice of forum deserves

considerable deference. Id. at 1. And it disputes Defendants’ claim that the Southern District would be more convenient. Id. at 2. Ultimately, Defendants have the better argument. III. LEGAL STANDARD

Even when venue is already proper, “[f]or the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought.” 28 U.S.C. § 1404(a). Assessing a transfer request requires an “individualized, case-by-case consideration of convenience and fairness.” Van Dusen v. Barrack, 376 U.S. 612, 622 (1964). The party who asks for a transfer bears the burden of showing it is warranted. Chauhan v. Napolitano, 746 F. Supp. 2d 99, 102 (D.D.C. 2010). First, the movant must demonstrate that venue would be proper in the proposed transferee district. Wolfram Alpha LLC v. Cuccinelli, 490 F. Supp. 3d 324, 330 (D.D.C. 2020). Second, the movant must show that the balance of private and public interests weighs in favor of transfer. Id.

IV. ANALYSIS The Commission does not disagree that venue would be proper in the Southern District of California. Nor could it, seeing as Illumina is headquartered there and GRAIL is headquartered

elsewhere in California. See 28 U.S.C. § 1391(b)(1) (stating that venue is proper in “a judicial district in which any defendant resides, if all defendants are residents of the State in which the district is located”); see also 15 U.S.C. § 53(b) (permitting the Commission to bring suit, inter alia, wherever venue is proper under section 1391). As a result, this dispute centers on whether private and public interests warrant transfer. Almost all those factors are neutral or favor transfer. But the one factor weighing in favor of keeping the case is ordinarily entitled to a great deal of deference. Although the

question is a close call, the Court agrees with Defendants that transfer is appropriate. A. The Effect of the COVID-19 Pandemic Before delving into an assessment of the private and public interest factors, the Court addresses how the ongoing COVID-19 pandemic affects its analysis. For over a year, courts across the country—including this one and the District Court for the Southern District of California—have held limited in-person hearings to slow the spread of the COVID-19 virus. See, e.g., Standing Order 20-9 (D.D.C. Mar. 16, 2020); Standing Order 18-A (S.D. Cal. Mar. 23, 2020). In the meantime, courts have mostly resorted to holding hearings over the telephone and videoconferencing software. But the proliferation of vaccines raises the possibility of returning to regular in-person proceedings soon. See COVID-19 Vaccinations in the United States, Ctr. for

Disease Control & Prevention, https://covid.cdc.gov/covid-data-tracker/#vaccinations (showing that, as of April 18, 2021, 25.4% of the U.S. population was fully vaccinated). The parties spar over how the possibility of an in-person preliminary injunction hearing impacts the appropriateness of transfer. Defendants want the hearing—which they say “will function as a trial on the merits”—to be in person. Defs.’ Mot. at 1. And if the hearing is in person, they say, then it would be much easier for witnesses and parties who largely reside in California and the Western United States to travel to the Southern District than it would be for them to travel to the District of Columbia. Id. at 1, 7. Defendants assert that the risk of contracting COVID-19 may dissuade West Coast witnesses’ attendance at a hearing on the other side of the country, and they point out that local D.C. travel restrictions (such as testing and isolation requirements) would raise logistical hurdles. See id. at 7–8; see also, e.g., D.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Mathis v. Geo Group, Inc.
535 F. Supp. 2d 83 (District of Columbia, 2008)
United States v. Brown University
772 F. Supp. 241 (E.D. Pennsylvania, 1991)
United States v. H & R Block, Inc.
789 F. Supp. 2d 74 (District of Columbia, 2011)
Walker v. Pharmaceutical Research & Manufacturers of America
461 F. Supp. 2d 52 (District of Columbia, 2006)
Pyrocap International Corp. v. Ford Motor Co.
259 F. Supp. 2d 92 (District of Columbia, 2003)
Commission v. Cephalon, Inc.
551 F. Supp. 2d 21 (District of Columbia, 2008)
Chauhan v. Napolitano
746 F. Supp. 2d 99 (District of Columbia, 2010)
Reiffin v. Microsoft Corp.
104 F. Supp. 2d 48 (District of Columbia, 2000)
Thayer/Patricof Education Funding, L.L.C. v. Pryor Resources, Inc.
196 F. Supp. 2d 21 (District of Columbia, 2002)
Bergmann v. United States Department of Transportation
710 F. Supp. 2d 65 (District of Columbia, 2010)
New Hope Power Co. v. United States Army Corps of Engineers
724 F. Supp. 2d 90 (District of Columbia, 2010)
Mazzarino v. Prudential Insurance Co. of America
955 F. Supp. 2d 24 (District of Columbia, 2013)
Virts v. Prudential Life Insurance Co. of America
950 F. Supp. 2d 101 (District of Columbia, 2013)
Bader v. Air Line Pilots Association, International
63 F. Supp. 3d 29 (District of Columbia, 2014)
Vasser v. Shinseki
72 F. Supp. 3d 269 (District of Columbia, 2014)
Beall v. Edwards Lifesciences LLC
310 F. Supp. 3d 97 (D.C. Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Federal Trade Commission v. Illumina Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/federal-trade-commission-v-illumina-inc-casd-2021.